Incyte posts terminated Phase 1 KRASG12C combo results; registers new INCB161734 mass balance study
Incyte reported results from a terminated Phase 1 trial of INCB099280 with adagrasib in KRASG12C tumors and registered a new healthy-volunteer study of INCB161734.
Incyte's week included one results posting from a discontinued oncology combination trial and one newly registered early-phase pharmacokinetics study.
- Incyte posted results for a Phase 1 study (NCT06039384) testing INCB099280 combined with adagrasib (Mirati Therapeutics' KRAZATI) in adults with advanced solid tumors harboring a KRASG12C mutation. The study was terminated as a strategic business decision, with no safety concerns contributing to the decision1, after enrolling 6 participants1 against a design meant to expand to up to 80 participants across NSCLC and colorectal cancer cohorts1.
- Incyte registered a new Phase 1 study (NCT07814404) of a single oral dose of [14C]-INCB161734 in healthy male participants to assess the mass balance, pharmacokinetics, and metabolite profiles2 of the drug. The trial is not yet recruiting2, with an estimated enrollment of 10 participants2 and an estimated start date of 2026-09-182.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.